Breast Cancer :: GSK seeks approval for lapatinib for breast cancer patients in Japan
GlaxoSmithKline K.K. (Head Office: Shibuya-ku, Tokyo, President: Marc Dunoyer, hereinafter referred to as GSK) announced the submission of a New Drug Application (NDA) to the Japanese authorities for approval to market lapatinib, its new cancer drug on 30 March.